Core Insights - Crinetics Pharmaceuticals granted stock options and restricted stock units (RSUs) to 20 new non-executive employees as part of its 2021 Employment Inducement Incentive Award Plan, totaling 78,975 shares in stock options and 54,475 shares in RSUs [1][2] Company Overview - Crinetics Pharmaceuticals is a global pharmaceutical company focused on transforming the treatment of endocrine diseases and related tumors, emphasizing patient needs and targeting G-protein coupled receptors (GPCRs) with small molecules [3] Product Pipeline - The lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the U.S. FDA for adults with acromegaly who have had inadequate surgical responses or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors [4] - Crinetics has a deep pipeline with over 10 disclosed programs, including atumelnant, which is in late-stage development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. Other discovery programs target various endocrine conditions such as Graves' disease, polycystic kidney disease, and GPCR-targeted oncology indications [4]

Core Insights - Crinetics Pharmaceuticals, Inc. will report its third quarter 2025 financial results on November 6, 2025, after market close, followed by a conference call at 4:30 p.m. ET to discuss the results and provide a business update [1] Company Overview - Crinetics Pharmaceuticals is a global pharmaceutical company focused on transforming the treatment of endocrine diseases and related tumors, emphasizing patient needs [4] - The company specializes in discovering, developing, and commercializing novel therapies, particularly targeting G-protein coupled receptors (GPCRs) with small molecules [4] Product Pipeline - Crinetics' lead product, PALSONIFY™ (paltusotine), is the first once-daily oral treatment approved by the U.S. FDA for adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option [5] - Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors [5] - The company has a deep pipeline of over 10 disclosed programs, including the late-stage investigational candidate atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome [5] - Additional discovery programs target various endocrine conditions such as neuroendocrine tumors, Graves' disease, polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications [5]

Core Points - Crinetics Pharmaceuticals granted stock options and RSUs to 20 new non-executive employees as part of its 2021 Inducement Plan to attract talent [1][2] - The stock options have an exercise price of $35.00 per share, equal to the closing price on September 10, 2025, and will vest over four years [2] - Crinetics is a clinical-stage pharmaceutical company focused on developing therapeutics for endocrine diseases and related tumors, with its lead candidate being PALSONIFY™ for acromegaly [3] Summary by Category Stock Options and RSUs - The Compensation Committee granted a total of 62,475 stock options and 43,800 RSUs under the 2021 Inducement Plan [1] - Stock options will vest over four years, with 25% vesting after one year and the remainder in 36 equal monthly installments [2] - RSUs will also vest over four years in equal annual installments starting from the one-year anniversary of the vesting commencement date [2] Company Overview - Crinetics Pharmaceuticals specializes in discovering and developing novel therapeutics for endocrine diseases and tumors [3] - The company’s lead candidate, PALSONIFY™, is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors [3] - Other development programs include treatments for congenital adrenal hyperplasia, Cushing's syndrome, and various endocrine conditions [3]

Core Insights - Crinetics Pharmaceuticals received Orphan Drug Designation from the FDA for atumelnant, a novel oral ACTH receptor antagonist aimed at treating classic congenital adrenal hyperplasia (CAH) [1][4] - Atumelnant is the first and only small molecule ACTH receptor antagonist in clinical development, highlighting its potential significance in addressing unmet medical needs in CAH [1][5] Company Overview - Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing novel therapeutics for endocrine diseases and related tumors, with all drug candidates being small molecules from in-house discovery efforts [6] - The company's lead candidate, PALSONIFY™ (paltusotine), is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors, while atumelnant targets congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome [6] Clinical Development - The Phase 2 TouCAHn trial of atumelnant showed robust positive topline results, including up to an 80% mean reduction in androstenedione and significant improvements in clinical signs and symptoms of CAH [2][3] - Crinetics plans to initiate the CALM-CAH Phase 3 study in adults and the BALANCE-CAH Phase 2/3 study in pediatrics in the second half of 2025 [2] Mechanism of Action - Atumelnant acts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal gland, demonstrating strong binding affinity and suppression of glucocorticoids and androgens controlled by ACTH [5] - The innovative mechanism aims to restore normal levels of adrenal androgens and reduce glucocorticoid supplementation to physiological levels, improving the quality of life for patients [2][3]